Acute Renal Failure (ARF) Market Projected For Strong Expansion Through 2030: Key Trends And Future Outlook
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Acute Renal Failure (ARF) Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The acute renal failure (arf) market has seen significant expansion in recent years. This market is expected to increase from $6.6 billion in 2025 to $7.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.3%. Historically, this growth has been driven by factors such as the growing incidence of hypertension and diabetes, the expansion of hospital-provided renal care services, a lack of early ARF symptom recognition, the continued use of conventional dialysis methods, and enhancements in hospital infrastructure.
The market size for acute renal failure (arf) is anticipated to demonstrate significant growth over the next few years. It is projected to expand to $9.71 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.0%. This projected growth during the forecast period is attributable to the development of novel nephroprotective drugs, the integration of AI-based diagnostics, the expansion of home healthcare services, an increasing geriatric population, and rising investment in renal disease research. Prominent trends expected in the forecast period include the increasing adoption of advanced dialysis and renal support therapies, a heightened focus on the early diagnosis of acute kidney injury, a growth in the use of nephroprotective drug therapies, the expansion of imaging and biopsy-based diagnostic techniques, and a growing preference for home healthcare management among arf patients.
Get A Free Sample Report With In-Depth Market Insights:
Acute Renal Failure (ARF) Market Development Factors: What’s Supporting Demand?
The expanding occurrence of chronic kidney diseases is anticipated to boost the acute renal failure (ARF) market in the coming years. Chronic kidney disease (CKD) is defined as a persistent condition where kidney damage hinders proper blood filtration. The growing incidence of CKD stems from increasing levels of diabetes, hypertension, obesity, aging populations, and lifestyle factors globally. Acute renal failure, marked by a sudden decrease in kidney function, can serve as a key initiator or intensifier for chronic kidney disease. This happens by inflicting permanent damage on kidney tissues, reducing filtration efficiency, and heightening the danger of progressive, long-term kidney dysfunction if not managed properly. For example, a June 2023 report from Kidney Research UK, a non-profit organization in the UK, indicated that approximately 7.2 million people in the UK currently suffer from chronic kidney disease, accounting for over 10% of the population. Among these, 3.25 million are in advanced stages, while 3.9 million are in early stages. Projections suggest that by 2033, the number of individuals with chronic kidney disease will climb to 7.61 million. Consequently, the rising prevalence of chronic kidney diseases is stimulating expansion in the acute renal failure (ARF) market.
Acute Renal Failure (ARF) Market Segment Landscape: Which Areas Lead Development?
The acute renal failure (arf) market covered in this report is segmented –
1) By Disease Type: Prerenal Acute Renal Failure, Renal Acute Renal Failure, Postrenal Acute Renal Failure
2) By Drug Type: Diuretics, Vasopressors, Erythropoiesis-Stimulating Agents (ESAS), Phosphate Binders, Calcium and Vitamin D Supplements, Antibiotics, Other Drugs
3) By Route of Administration: Oral, Intravenous
4) By End-Users: Clinics, Hospitals, Others End-Users
Subsegments:
1) By Prerenal Acute Renal Failure: Hypovolemia, Decreased Cardiac Output, Renal Artery Stenosis
2) By Renal Acute Renal Failure: Acute Tubular Necrosis, Glomerulonephritis, Interstitial Nephritis
3) By Postrenal Acute Renal Failure: Obstructive Uropathy, Bladder Outlet Obstruction, Kidney Stones
Acute Renal Failure (ARF) Market Transformation Trends: What Innovations Are Driving Change?
Leading companies in the acute renal failure (ARF) market are primarily focused on securing regulatory authorizations for their medications to expand their market reach and strengthen their position in treating severe acute kidney injury (AKI). Regulatory approvals signify official permission from government or regulatory bodies for the marketing and general public use of drugs, medical devices, or therapies. For example, in February 2024, CalciMedica, a US-based clinical-stage biopharmaceutical firm, obtained FDA approval for an IND application to commence a Phase 2 trial of Auxora. This trial aims to evaluate Auxora’s effectiveness in addressing severe acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF), a condition characterized by a high mortality rate. The KOURAGE trial is a randomized, double-blind, placebo-controlled study slated to enroll approximately 150 patients with Stage 2 and 3 acute kidney injury (AKI) who also suffer from acute hypoxemic respiratory failure (AHRF), evaluating Auxora’s efficacy over five daily doses by assessing the number of days a patient remains alive without needing ventilators or dialysis for up to 30 days post-treatment.
Acute Renal Failure (ARF) Market Industry Leaders And Competitive Landscape
Major companies operating in the acute renal failure (arf) market are Pfizer Inc, Novartis AG, Baxter International Inc, Fresenius Medical Care AG and Co KGaA, Medtronic plc, Asahi Kasei Corporation, Astellas Pharma Inc, NIKKISO Co Ltd, NIPRO Corporation, Quark Pharmaceuticals Inc, AM Pharma BV, Sentien Biotechnologies, Angion Biomedica Corp, Alloksys Life Sciences BV, Theravance Biopharma, Kissei Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, B Braun Melsungen AG, Chiesi Farmaceutici SpA, Takeda Pharmaceutical Company Limited
View The Full Acute Renal Failure (ARF) Market Report:
Acute Renal Failure (ARF) Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the acute renal failure (ARF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute renal failure (arf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
